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We describe a retrospective series of patients with advanced head-and-neck cancer who were treated with induction chemotherapy
followed by radical chemo-radiation. Patients treated with two cycles of induction chemotherapy followed by definitive chemo-
radiation for squamous cell carcinoma of the head-and-neck region, from 2001 – 2006 at the Royal Marsden Hospital, formed the
basis of this study. Cisplatin (75mgm
 2) on day 1 and 5-FU (1000mgm
 2) day 1 – 4 was the standard regimen used for induction
treatment. Cisplatin (100mgm
 2) on day 1 and day 29 was used for concomitant treatment. The radiation was delivered using
conformal technique. Tissues containing macroscopic and microscopic disease were treated to doses of 65 Gray (Gy) in 30 fractions
and 50Gy in 25 fractions, respectively. Data on patterns of relapse and acute toxicity (NCICTCv.3.0) were collected. A total of 129
patients were included, median age was 58 (range: 27 – 78). The site of tumour was: oropharynx 70 (54%), larynx 30 (23%),
hypopharynx 24 (19%) and other 5 (4%). The median follow-up was 19 months (range: 4 – 58). Local control, disease-specific
survival and overall survival at 2 years were 71%, 68% and 63%, respectively. The distant recurrence rate at 2 years was 9%. Ten
patients required dose reduction during induction chemotherapy due to toxicity. The dose of 5-FU was reduced in six patients and
that of cisplatin in four patients. The incidence of grade 3/4 toxicity was: neutropenia 5%, thrombocytopenia 1%, nausea and vomiting
3%. One cycle of concurrent cisplatin was omitted in 23 patients due to toxicity. Full-dose radiotherapy was administered to 98% of
patients. The incidence of grade 3/4 toxicity was: skin 20%, dysphagia 65%, mucositis 60%, neutropenia 3%, anaemia 1%, nausea and
vomiting 4%, nephrotoxicity 1%. Induction chemotherapy followed by radical chemo-radiation is a safe and tolerable regimen in the
treatment of advanced head-and-neck cancer. Distant recurrence rates are lower with equivalent local control and survival compared
to chemo-radiation alone (historical controls).
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Surgery and radiotherapy are the mainstays of treatment for head-
and-neck cancer patients. However, in recent years, systemic
chemotherapy has been increasingly incorporated into the
treatment plan in patients with stages III and IV disease. As part
of the primary treatment, systemic chemotherapy can be
administered before (induction chemotherapy), or during radio-
therapy (concomitant chemotherapy). Meta-analysis showed that
concurrent chemotherapy confers an absolute survival benefit of
8% (Pignon et al, 2000). Concurrent chemo-radiation is the
current standard of care as the first line treatment for stages III
and IV disease. Two recent trials have also reported on the benefit
of concomitant chemo-radiotherapy in the post-operative setting
for high-risk patients (Bernier et al, 2005). In contrast, the role of
induction chemotherapy is not yet clear. Although not the
standard of care, induction chemotherapy is used in clinical
practice and is thought to be beneficial for reducing the rate of
distant metastases (Paccagnella et al, 1994; Lefebvre et al, 1996),
increasing organ preservation (Group, 1991; Lefebvre et al, 1996)
and survival rates (Paccagnella et al, 1994; Zorat et al, 2004).
Combining induction and concomitant chemotherapy with radia-
tion, that is, in a sequential treatment approach, has the potential
for improving disease outcomes.
A combination of cisplatin (75 – 100mgm
 2) and 5-fluorouracil
(5-FU, 750 – 1000mgm
 2 for 5 days) every three weeks is the most
commonly used regimen for induction treatment. Single-agent
cisplatin is the cytotoxic agent of choice for concomitant chemo-
radiotherapy. The majority of clinical trials reported in the
literature have not used these standard aforementioned regimens.
At our institution, two cycles of induction cisplatin (75mgm
 2)
plus 5-FU (1000mgm
 2 for 4 days) followed by radical chemo-
radiation with two cycles of cisplatin (100mgm
 2) has been the
standard of care for patients with stages III and IV head-and-neck
cancer since 2001. This regimen was initiated in response to a
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sdesire to deliver short-course induction chemotherapy during the
waiting period (average 4 weeks in 2001) for planning and
commencing radiotherapy. The relatively conservative dosing of
cisplatin (75 rather than 100mgm
 2) and 5-FU (4 rather than 5
days) was an attempt to limit the risk that chemotherapy-induced
toxicity might delay the start of chemo-radiotherapy, which is
considered to be the most important curative component of the
treatment approach. Similarly, the decision to restrict induction
chemotherapy to two, rather than three or four, cycles was
motivated by the wish to commence chemo-radiotherapy as soon
as possible after the planning process was complete. In this report,
we present data on the toxicity and outcomes for the retrospective
study performed using this regimen in advanced head-and-neck
cancer.
MATERIALS AND METHODS
From January 2001 to September 2006, 145 consecutive patients
with head-and-neck cancer were treated at the Royal Marsden
Hospital with two cycles of induction chemotherapy followed by
radical chemo-radiation (CRT). This report provides data on
patients with an established primary tumour of squamous cell
(SCC) histology. Patients who presented with carcinoma of the
nasopharynx (regardless of WHO type), with WHO performance
status two and above, or a tumour of unknown primary origin are
not included in this report. All patients were reviewed in a
multidisciplinary team meeting before the start of treatment. Our
institutional policy is to offer organ-preserving treatment to all
patients with locally advanced head-and neck-cancers. Therefore,
specific data on whether, or not, a tumour was technically operable
at diagnosis were not available.
Chemotherapy schedule
The induction chemotherapy regimen for locally advanced head-
and-neck cancer was two cycles of platinum-based chemotherapy
followed by 4 days of 5-FU given on a 21-day cycle. The majority of
patients received cisplatin chemotherapy 75mgm
 2 day 1 with
5-FU 1gm
 2 day 1 – 4. This dose of cisplatin was selected in an
attempt to limit adverse effects in our unselected population of
patients and to maximise the number of patients who were able to
receive cisplatin during concomitant CRT. Patients who had poor
renal function at the outset (glomerular filtration rate of o60ml
per min
 1) received carboplatin-5 fluorouracil and concomitant
carboplatin. These patients were excluded from the analysis.
Concomitant cisplatin (100mgm
 2 on days 1 and 29) was
administered as two, rather than three, cycles to allow us to
employ our standard modestly accelerated hypofractionated
radiotherapy regimen.
Radiation delivery
All patients received a radiobiological equivalent dose of 70Gy in
35 fractions to the tumour and high-risk nodal groups. The
majority of patients were treated using a radiotherapy fractiona-
tion of 65Gy in 30 fractions over 6 weeks. The last week of
treatment was given as an accelerated hypofractionated course of
15Gy in five fractions. Elective nodes received 50Gy in 25 fractions
at conventional fractionation. During the radiotherapy, concomi-
tant cisplatin was given at 100mgm
 2 on days 1 and 29. All
patients receiving other fractionation regimens were included,
provided they were planned to receive a biologically equivalent
dose (BED) equal to or greater than our standard fractionation.
Patients who were planned with 2D, 3D conformal or intensity-
modulated radiotherapy were included in the analysis, provided
they were planned to receive both induction and concomitant
chemotherapy. Patients who had residual disease at the end of
their course of treatment were referred for salvage surgery,
provided their disease was operable. Patients who present with
node-positive disease underwent a neck dissection after chemo-
radiation, unless they achieved complete response (CR) as per the
departmental policy.
Outcome measures
Data on patient demographics and stage were collected. Patients
were staged using radiology (CT and/or MRI) and an examination
under anaesthesia and biopsy. Response rates to induction
chemotherapy and to CRT were assessed clinically and radiologi-
cally. Radiological responses were recorded according to RECIST
criteria. A patient was deemed to have had a CR, if there was no
evidence of disease either clinically or on imaging following CRT
(and salvage surgery when required). Time to disease progression
was measured form the date of diagnosis to the time of first
recurrence. Survival was measured form the date of diagnosis to
the date of death. Toxicities for induction and CRT were recorded
and graded from 1 – 4 according to the Common Terminology
Criteria for Adverse Events v3.0 (CTCAE) (DCTD, 2003). Patients
were not reviewed weekly during induction chemotherapy and
blood tests were limited to occasions when the patients were
attending the hospital for radiotherapy planning appointments.
Therefore, it is likely that the documented haematological and
biochemical toxicities may be an underestimate of the true values.
During chemo-radiotherapy, patients were reviewed weekly and
underwent weekly blood tests. Routine baseline audiometry was
not performed and evaluation of ototoxicity was based on clinical
assessment.
Statistical analysis
Local control, disease-specific and overall survival rates at 2 years
were obtained using Kaplan—Meier survival curves. Data for
patients lost to follow-up or whose follow-up did not reach 2 years
was censored. Local control rate was defined as the proportion of
patients who were free of local recurrence at 2 years. Disease-
specific survival rate defined the percentage of patients who were
free of their head-and-neck cancer at 2 years. Univariate analyses
were performed for gender, T and N stages, age, smoking status,
alcohol ingestion, site and stage of disease followed by a
multivariate analysis.
RESULTS
Of the initial 145 consecutive patients, 129 are included in the final
analysis. Sixteen patients who had received carboplatin throughout
their treatment were excluded from analysis. The patient demo-
graphics and TNM staging are listed in Tables 1 and 2, respectively.
The median follow-up was 19 months (range: 4 – 58). The majority
of patients were found to have stage III/IV tumours. Two patients
had stage II tumours (T2N0M0) and one stage I. One of these
patients had a bulky transglottic laryngeal carcinoma, while the
other had a bulky T2 tonsillar tumour extending to midline.
Toxicity
A total of 119 patients completed full-dose induction chemo-
therapy. Ten patients required dose reduction during induction
chemotherapy due to toxicity. One patient had grade 3 diarrhoea,
three patients had grade 4 haematological toxicity, two patients
had dose-limiting renal toxicity and four had dose-limiting cardiac
toxicity. Four more patients had cardiac toxicity during induction
chemotherapy, which was not considered to be dose limiting. Of
the eight patients who developed cardiac toxicity, three developed
atrial fibrillation and five developed coronary vasospasm and chest
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spain. The dose of 5-FU was reduced in six patients and that of
cisplatin in four patients. The incidence of grade 3/4 toxicity was:
neutropenia 5%, thrombocytopenia 1%, nausea and vomiting 3%
(Table 3). Overall, induction chemotherapy in this group of
patients was tolerated well. A total of 106 patients (82%) completed
the full course of concomitant cisplatin. In the remaining patients,
cisplatin was replaced by carboplatin (AUC5) for the second cycle
due to toxicity. One hundred and twenty-seven (98%) patients
completed the full course of radiotherapy. One patient missed the
last two fractions due to radiation-induced laryngeal oedema. The
second patient missed the last six fractions of treatment due to
upper gastrointestinal bleed from a duodenal ulcer. The incidence
of grade 3 toxicity was: skin 26%, dysphagia 85%, mucositis 78%,
neutropenia 3%, anaemia 1%, nausea and vomiting 4% and
nephrotoxicity 1% (Table 3). No grade 4 toxicity was seen during
chemo-radiation. There were no deaths related to toxicity during
induction chemotherapy and chemo-radiation.
Ten patients developed grade 3/4 late radiation toxicity at 1 year.
Two patients had osteoradionecrosis of the mandible; seven
patients had persistent dysphagia from abnormal anterior
laryngeal movement and narrowing at the cricopharyngeal inlet
and one patient had laryngeal necrosis. Three patients required
laryngo-pharyngectomy for late radiation toxicity and one patient
was successfully treated with oesophageal dilatation.
Response rate
At the end of two cycles of induction chemotherapy, seven (5.4%)
achieved radiological CR, 92 (71.3%) patients achieved partial
response (PR) and 30 (23%) patients had stable disease (SD). At
the end of CRT, residual disease remained in 13 of 92 (14.1%)
patients who had had a PR and 14 of 30 (46.7%) patients who had
had SD. A total of 102 (79.1%) patients achieved a CR; residual
disease was present at the end of treatment in 27 patients. Of these
27 patients, 18 had biopsy-proven residual disease at the end of
treatment. Ten patients underwent salvage surgery. Out of the
remaining 17 patients, 12 remained inoperable at the end of
treatment. Only one patient was operable at initial diagnosis. Two
patients refused salvage surgery and two patients were considered
to be medically unfit for surgery.
Local control rate
The loco-regional control rates were 75% (95% CI: 67 – 82%) and
71% (95% CI: 62 – 79%) at 1 year and 2 years, respectively
(Figure 1). Among the patients with laryngeal/hypopharyngeal
cancer, 13 (24%) developed local recurrence, one of whom had a
nodal recurrence. Six patients underwent salvage laryngo-phar-
yngectomy, one patient refused surgery and the remaining patients
were considered inoperable. The laryngeal preservation rate (for
patients with laryngeal/hypopharyngeal cancer) at 2 years was
62%. Eight (9%) out the 92 patients who had Nþ disease at
presentation had nodal recurrence. Two underwent neck dissec-
tion and six were considered to be inoperable. Various factors
analysed by using univariate analysis are listed in Table 4. T stage
(P¼0.009) remained the only significant factor on multivariate
analysis.
Survival
The overall survival at 2 years was 63% (95% CI: 53 – 71%). Overall
survival is demonstrated in Figure 2. Various factors analysed by
using univariate analysis are listed in Table 4. T (P¼0.001) and N
stages (P¼0.018) were significant factors on univariate analysis.
However, on multivariate analysis, the only factor affecting overall
survival was T stage (Po0.001). N stage was not significant on
multivariate analysis (P¼0.06). When nodal status was broken
down according to N0/N1 or N2/N3, it was still not significantly
associated with survival on multivariate analysis (P¼0.06), The
median survival for all patients was 3.2 years (95% CI: 2.6 – 3.7).
The disease-specific survival (DSS) at 2 years was 68% (95% CI:
58 – 76%). At the time of the analysis, median DSS was not reached
(Figure 3). Various factors analysed using univariate analysis are
listed in table, only T (P¼0.005) and N stages (P¼0.007) were
significant. On multivariate analysis, these factors remained
significant (T stage (P¼0.035), N stage (P¼0.029)). Of the
patients who died from head-and-neck cancer, 84% died due to
uncontrolled or relapsed loco-regional disease.
The rate of freedom from distant metastases was 93 and 91% at 1
and 2 years, respectively. There were 12 deaths from intercurrent
Table 2 TNM staging distribution
T/N Stage N0 N1 N2a N2b N2c N3 Total
T1 1 0 3 1 0 0 5
T2 2 8 4 8 7 1 30
T3 21 12 4 5 9 6 57
T4 12 6 1 10 3 5 37
Total 36 26 12 24 19 12 129
Table 1 Patient demographics
Number of patients 129
Sex
Male 78 (76%)
Age(years)
Median (range) 58 (27 – 78)
Smokers 95 (74%)
Site
Oropharynx 70 (54%)
Larynx 30 (23%)
Hypopharynx 24 (19%)
Oral cavity 3 (2.3%)
Paranasal sinuses 2 (1.7%)
Stage
I 1 (0.8%)
II 2 (1.6%)
III 48 (37.2%)
IV 78 (60.5%)
Table 3 Toxicity during neo-adjuvant chemotherapy and CRT
Neo-adjuvant
chemotherapy CRT
Grades 1/2 Grades 3/4 Grade 1/2 Grade 3
Anaemia (%) 26 (20) 0 71 (55) 2 (1.5)
Neutropenia (%) 17 (13) 7 (5) 26 (20) 4 (3)
Thrombocytopenia (%) 1 (0.8) 1 (0.8) 5 (4) 0
Ototoxicity (%) 1 (0.8) 0 0 0
Nausea and Vomiting (%) 13 (10) 4 (3) 15 (11) 5 (4)
Neurotoxicity (%) 0 0 1 (0.8) 0
Cardiac toxicity (%) 8 (6) 0 NA NA
Nephrotoxicity (%) 5 (4) 0 8 (6) 1 (0.8)
Skin reaction (%) NA NA 103 (77) 26 (23)
Mucositis (%) 0 0 51 (40) 78 (60)
Dysphagia (%) NA NA 36 (28) 85 (72)
NA¼not applicable.
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(six non-small cell lung cancer, two oesophageal cancer, one breast
cancer); one patient died of respiratory infection; one patient died
of cerebrovascular disease and one patient died of myocardial
infarction.
DISCUSSION
The patients in our study had a 2-year local control rate of 71%,
DSS of 68%, overall survival of 63%. We identified only one study
in the literature using a treatment regimen similar to ours (Psyrri
et al, 2004). Psyrri et al (2004) reported on a phase II study with 42
patients with stages III and IV head-and-neck cancer patients. At 2
years, the authors reported a local control rate of 76.3%, DSS of
69%, overall survival of 66.7% and rate of control of distant
metastases of 79%. This study included patients with nasophar-
yngeal tumours, which have a better stage for stage outcome
compared to tumours at other head-and-neck sites. This might
account for the slightly inferior outcomes in our study.
Two other studies using cisplatin and 5-FU for induction and
cisplatin alone for concomitant treatment have been reported in
the literature. The study by Hitt et al, 2005 (189 patients) used
three cycles of induction and concomitant chemotherapy. This was
compared in a randomised setting to an induction regimen that
included paclitaxel. The SWOG study (42 patients) used two cycles
of induction treatment but three cycles of concomitant chemo-
therapy (Urba et al, 2005). The overall survival at 2 years in the
Hitt study was 53.6% in the control arm (without paclitaxel).
The overall survival in the SWOG study at 3 years was 64%. The
superior results in the SWOG study might be due to the exclusion
of patients with T4 tumours. The rates of local control or the DSS
were not stated in the published reports of these studies.
Chemo-radiation is the standard treatment for patients with
advanced head-and-neck cancer. Table 5 summarizes the disease
outcomes from a few published trials using chemo-radiation for
treatment of advanced head-and-neck cancer. The 2-year loco-
regional control rate (71%) and overall survival (63%) in our study
was superior to the studies with reported 2-year outcomes. This
could be due to a combination of low nodal recurrence rates (9%)
in patients with Nþ disease and reduced rate of distant
metastases. This is consistent with the Pignon meta-analyses
where the analyses of trials using the cisplatin and 5-FU regimen
for induction treatment showed an absolute survival benefit of 5%
(Pignon et al, 2000).
Organ conservation is one of the rationales for induction
chemotherapy (Group, 1991; Lefebvre et al, 1996). In our study, the
laryngeal preservation rate at 2 years was 62%. This included
patients who had died without loco-regional recurrence and
therefore had an intact larynx at the time of death. This rate is
comparable to the other studies. In the phase II studies, using the
sequential approach by Psyrri et al (Psyrri et al, 2004) and the
SWOG study (Urba et al, 2005), the larynx preservation rates were
64.3 and 64%, respectively.
Table 4 Univariate analysis of potential factors affecting disease
outcomes
P-values
Factor tested
Local
control
Disease specific
survival
Overall
survival
T-stage 0.001 0.005 0.001
N-stage 0.423 0.007 0.018
Gender 0.749 0.827 0.734
Site of cancer 0.110 0.549 0.702
Age (o60 vs X60) 0.960 0.724 0.963
Stage (III and IV) 0.531 0.208 0.108
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Figure 1 Kaplan—Meier estimates of local control.
Overall survival
100
80
60
40
20
0
%
 
s
u
r
v
i
v
i
n
g
0123456
Number at risk Years from diagnosis
128 93 45 24 9
Figure 2 Kaplan—Meier estimates of overall survival.
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Figure 3 Kaplan—Meier estimates of disease-free survival.
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sIt has been postulated that the induction chemotherapy reduces
the rates of distant metastases (Paccagnella et al, 1994; Lefebvre
et al, 1996). In our study, the rate of freedom from distant
metastases was 91% at two years. This is comparable to other
studies using the sequential approach: Psyrri et al (2004; 79%),
Machtay et al (84%) and Vokes et al (93%). It is better than the
rate of distant metastases in trials using chemo-radiation alone
(see Table 5).
Treatment-related toxicity in our study was not excessive. A
total of 90% of the patients completed full-dose induction
treatment and 82% of the patients had full-dose concomitant
cisplatin. None of the patients required treatment gaps during
chemo-radiation due to the toxicity. Although, the incidence of
acute toxicity during chemo-radiation was quite significant, it was
transient and the majority of patients recovered. Enteral feeding
was required in 85% of our patients due to severe mucositis. This
is much higher than that reported for trials using chemo-radiation
alone (33 – 44%). However, most of these patients recovered and
only four patients (3%) required enteral support after 1 year. This
rate is considerably lower than the rates of late feeding tube
dependence (24 – 50%) in other series.
The overall survival in this group of patients leaves scope for
improvement. Phase II studies have been conducted using taxanes
in addition to cisplatin and 5-FU (Colevas et al, 1999; Posner et al,
2001). These have shown better response rates and tolerable
toxicity levels. There have been three randomised trials adding
taxanes to the standard sequential approach. In one study,
paclitaxel was added to cisplatin and 5-FU in the experimental
arm (Hitt et al, 2005). Although the response rates were better in
the experimental arm, there was no significant difference in the
overall survival (51 vs 43%, P¼0.063). Furthermore, the design of
that study incorporated a planned neck dissection between the
induction chemotherapy and chemo-radiotherapy phases of
treatment. In our view, this represented a suboptimal approach,
since the delay for surgery and wound healing potentially provided
an opportunity for repopulation at the primary tumour site.
Therefore, when those data were published, we decided to continue
to treat patients with our standard protocol of induction cisplatin/
5-FU followed by chemoradiation. More recently, two phase II
studies have been published (EORTC24971/TAX323 and TAX 324)
in which docetaxel was added to cisplatin and 5-FU in the
experimental arm for induction treatment (Posner et al, 2007;
Vermorken et al, 2007). The study by Vermorken et al (2007)
showed a survival benefit for the docetaxel arm but the overall 2-
year survival (43%) was lower than in our study or other reported
studies using the sequential approach. However, this study
exclusively included patients with unresectable disease and
concomitant chemotherapy was not used. Therefore, it is difficult
to draw any conclusions from this study with regard to the benefit
of taxanes in patients treated using the sequential approach.
Posner et al (2007), demonstrated a statistically significant 2-year
survival of 68% for the TPF arm vs 55% for the PF arm using the
sequential approach but that study employed an unconventional
concomitant regimen of carboplatin AUC 1.5 every week. It is
possible that the statistically significant difference observed in the
TAX 324 study could be due to a suboptimal control arm, that is,
using carboplatin instead of cisplatin for concomitant treatment.
This supposition is further supported by the 63% 2-year survival
for PF followed by CRT in our study, which was superior to the
control arm of the TAX 324 study. Currently, there are no data for
a head-to-head comparison of carboplatin vs cisplatin in this
setting, but the meta-analysis most strongly supports the use of
cisplatin for concomitant treatment (Pignon et al, 2000). Thus,
until randomised data are published from studies that employ
standard cisplatin-based concomitant regimens, it is difficult to
draw definitive conclusions on the utility of taxanes as part of
induction chemotherapy regimens.
Patients with oropharyngeal cancers comprised the largest
group (54%) in this study. This observation is important, because
it is known that a subset of these tumours have a different
aetiology (human papilloma virus (HPV) infection) and a better
prognosis when compared with ordinary tobacco- and alcohol-
induced cancers (Weinberger et al, 2006; Psyrri and DiMaio, 2008).
However, this percentage of patients with oropharyngeal cancers is
typical of other large treatment series, including the two recently
published phase III trials of taxane-containing induction chemo-
therapy (Posner et al, 2007; Vermorken et al, 2007). In those
studies, patients with oropharyngeal tumours comprised 46 and
53% of the treated subjects, respectively. Therefore, although we
do not have data on the number of patients with HPV-related
tumours in our series, it is likely that the rates would have been
comparable to those in other series.
CONCLUSIONS
This study shows the results of induction chemotherapy using the
PF regime followed by radical CRT forms as a baseline for
investigation of new treatments in advanced head-and-neck
cancer. Randomised phase III trials comparing the standard
sequential approach (using cisplatin and 5-FU) to concomitant
chemo-radiation (using cisplatin) are required to provide a
definite answers to the questions regarding the benefit of induction
chemotherapy.
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